DALLAS – May 10, 2018 – The START trial has opened at UT Southwestern for recruitment. The study seeks to define the Optimal Delay Time to Initiate Anticoagulation after Ischemic Stroke in Atrial Fibrillation (afib). Dr. Ty Shang is PI and Cheyenne Marcelus, MS, CCRP, is research coordinator.
START is a pragmatic, adaptive randomized trial to determine the optimal time to initiate NOAC anticoagulant therapy after ischemic stroke in patients with non-valvular atrial fibrillation. This study will not deviate from the treating physician’s usual practice except for randomizing the time to start the NOAC to one of four time-to- treatment delays from symptom onset. Recruitment and follow up will take place over a period of 48 months.
This study will be conducted in the Lone Star Stroke Consortium (LSS) Clinical Trials Network, and is funded by the Texas State Legislature. Dr. Goldberg is the hub PI for LSS.